Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2019

View Archived Issues

How blood flows through bones

F-act-in stead of MMPs

Metabolism change stimulates macrophage appetite

FDA approves sNDA to add moderate to severe vaginal dryness to the indication of Osphena

Momenta begins phase I/II trial of M-254 for ITP

Bacterial metabolites enhance immune responses

Axsome Therapeutics initiates phase II CONCERT study of AXS-12 in narcolepsy

RESMAIN study of resminostat receives second positive safety review

Ebola virus disease macaque model developed to aim at FDA approval

Fexinidazole approved in Democratic Republic of Congo for the treatment of sleeping sickness

FDA issues complete response letter for Sunovion's apomorphine sublingual film

Daewoong Pharmaceutical discloses Bruton tyrosine kinase/tyrosine-protein kinase ITK/TSK inhibitors

Tachykinin receptor 3 antagonists synthesized at Ogeda

A*STAR identifies MAPK-interacting kinase 1 and 2 inhibitors

Valneva reports final phase I and initial booster data with Lyme disease vaccine candidate VLA-15

Bristol-Myers Squibb discovers Rho-associated protein kinase 2 inhibitors

aTyr enters research collaboration with University of Nebraska in support of ATYR-1923

Hepatitis B virus caspid assembly inhibitors patented by Shanghai Longwood Biopharmaceuticals

Interim results from phase III study of oral ibrexafungerp in refractory fungal infections

Vertex Pharmaceuticals patents sodium channel protein type 10 subunit alpha blockers

Phase II trial explores use of oral factor XIa inhibitor BMS-986177 for secondary stroke prevention

CONRAD enrolls women in Kenya to study tenofovir/levonorgestrel and tenofovir intravaginal rings

5AR targeting disrupts D1R-D3R heteromer formation and protects from dyskinesia in Parkinson's model

TLR3 unveiled as therapeutic target for treating pulmonary hypertension

Imprinting of nc886 DMR is mosaic in the population and influenced by maternal environment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...